Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma

被引:45
作者
Onnis, A. [1 ]
Navari, M. [1 ]
Antonicelli, G. [1 ]
Morettini, F. [1 ]
Mannucci, S. [1 ]
De Falco, G. [1 ]
Vigorito, E. [2 ]
Leoncini, L. [1 ]
机构
[1] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy
[2] Babraham Inst, Lab Lymphocyte Signalling & Dev ISP, Cambridge, England
来源
BLOOD CANCER JOURNAL | 2012年 / 2卷
关键词
Epstein-Barr virus; microRNAs; Burkitt lymphoma; VIRUS; P53; MECHANISM; DISTINCT;
D O I
10.1038/bcj.2012.29
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epstein-Barr Virus (EBV) is a gamma-herpesvirus that infects >90% of the human population. Although EBV persists in its latent form in healthy carriers, the virus is also associated with several human cancers. EBV is strongly associated with Burkitt lymphoma (BL), even though there is still no satisfactory explanation of how EBV participates in BL pathogenesis. However, new insights into the interplay between viruses and microRNAs (miRNAs) have recently been proposed. In particular, it has been shown that B-cell differentiation in EBV-positive BL is impaired at the post-transcriptional level by altered expression of hsa-miR-127. Here, we show that the overexpression of hsa-miR-127 is due to the presence of the EBV-encoded nuclear antigen 1 (EBNA1) and give evidence of a novel mechanism of direct regulation of the human miRNA by this viral product. Finally, we show that the combinatorial expression of EBNA1 and hsa-miR-127 affects the expression of master B-cell regulators in human memory B cells, confirming the scenario previously observed in EBV-positive BL primary tumors and cell lines. A good understanding of these mechanisms will help to clarify the complex regulatory networks between host and pathogen, and favor the design of more specific treatments for EBV-associated malignancies.
引用
收藏
页码:e84 / e84
页数:8
相关论文
共 43 条
[1]   How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? [J].
Allday, Martin J. .
SEMINARS IN CANCER BIOLOGY, 2009, 19 (06) :366-376
[2]   Developing animal models for polymicrobial diseases [J].
Bakaletz, LO .
NATURE REVIEWS MICROBIOLOGY, 2004, 2 (07) :552-568
[3]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[4]   Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas [J].
Bellan, C ;
Lazzi, S ;
Hummel, M ;
Palummo, N ;
de Santi, M ;
Amato, T ;
Nyagol, J ;
Sabattini, E ;
Lazure, T ;
Pileri, SA ;
Raphael, M ;
Stein, H ;
Tosi, P ;
Leoncini, L .
BLOOD, 2005, 106 (03) :1031-1036
[5]   Germinal centers in human lymph nodes contain reactivated memory B cells [J].
Bende, Richard J. ;
van Maldegem, Febe ;
Triesscheijn, Martijn ;
Wormhoudt, Thera A. M. ;
Guijt, Richard ;
van Noesel, Carel J. M. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2007, 204 (11) :2655-2665
[6]   Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: An unresolved issue [J].
Bornkamm, Georg W. .
SEMINARS IN CANCER BIOLOGY, 2009, 19 (06) :351-365
[7]   Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: More questions than answers [J].
Bornkamm, Georg W. .
INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (08) :1745-1755
[8]   Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways [J].
Cameron, Jennifer E. ;
Yin, Qinyan ;
Fewell, Claire ;
Lacey, Michelle ;
McBride, Jane ;
Wang, Xia ;
Lin, Zhen ;
Schaefer, Brian C. ;
Flemington, Erik K. .
JOURNAL OF VIROLOGY, 2008, 82 (04) :1946-1958
[9]  
Claudio PP, 2000, CANCER RES, V60, P372
[10]   Role of EBV in microRNA dysregulation in Burkitt lymphoma [J].
De Falco, Giulia ;
Antonicelli, Giuseppina ;
Onnis, Anna ;
Lazzi, Stefano ;
Bellan, Cristiana ;
Leoncini, Lorenzo .
SEMINARS IN CANCER BIOLOGY, 2009, 19 (06) :401-406